InvesTech Holdings Enters into MoU with Huawei to Offer Cloud-based Enterprise Application Solutions
InvesTech Holdings Enters into MoU with Huawei to Offer Cloud-based Enterprise Application Solutions

HONG KONG, Aug 25, 2022 – (ACN Newswire via SEAPRWire.com) – InvesTech Holdings Limited (“InvesTech Holdings”, together with its subsidiaries, “the Group”; stock code: 1087.HK), a leading integrated smart-IT solutions provider in China, is pleased to announce that its subsidiary Wafer Systems (Asia) Limited (“Wafer Systems”), which owns smart-office software solutions flagship product Virsical, has... » read more

FMC 2022 “Video Game Scoring Competition” offers an exclusive opportunity for composers from around the world
FMC 2022 “Video Game Scoring Competition” offers an exclusive opportunity for composers from around the world

London, UK, Aug 25, 2022 – (ACN Newswire via SEAPRWire.com) – Every year, FMC-Film Music Contest – the unique international music competition and awards – provides a competitive platform for composers, musicians, producers, and sound designers of original scores for film, television, commercials and video games. FMC includes the “FMC Video Game Scoring Competition”, a... » read more

光大环境以创新促转型 领航「双碳」时代

HONG KONG, Aug 25, 2022 – (亚太商讯 via SEAPRWire.com) – 亚洲环保领军企业光大环境（257.HK）日前公布了今年上半年业绩，显示公司在挑战重重的经营环境中，仍然着力于加...

Paribus (PBX) Announces Multichain Integration and Partnership
Paribus (PBX) Announces Multichain Integration and Partnership

MIAMI, FL, Aug 25, 2022 – (ACN Newswire via SEAPRWire.com) – As our regular readers know we’ve been using the extra time our testnet deployment afforded us to equip Paribus with the optimal conditions for our mainnet launch. As part of that process, we’re absolutely thrilled to share with the community that we’ve partnered with... » read more

维信金科2022中期实现稳健业绩
维信金科2022中期实现稳健业绩

HONG KONG, Aug 24, 2022 – (亚太商讯 via SEAPRWire.com) – 中国领先的独立在线消费金融供货商维信金科控股有限公司（「维信金科」或「集团」; 股票编号：2003.HK）欣然...

VCREDIT 1H2022 Achieves a Solid Performance
VCREDIT 1H2022 Achieves a Solid Performance

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – VCREDIT Holdings Limited (“VCREDIT” or the “Group”; stock code: 2003.HK), a leading independent online consumer finance provider in China, announced its unaudited interim results for the 6 months ended 30 June 2022 (the “Period”). During the Period, the Group achieved a solid performance from... » read more

Zhaoke Ophthalmology Announces 2022 Interim Results
Zhaoke Ophthalmology Announces 2022 Interim Results

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, today announced its interim results for the six months ended 30 June... » read more

兆科眼科公布2022中期业绩
兆科眼科公布2022中期业绩

HONG KONG, Aug 24, 2022 – (亚太商讯 via SEAPRWire.com) – 致力于眼科疗法的研究、开发及商业化，以满足中国国内巨大医疗需求缺口的领先眼科制药企业兆科眼科有限公司（「兆科眼...

Subang Parade Holds Merdeka Fiesta to Celebrate National Day
Subang Parade Holds Merdeka Fiesta to Celebrate National Day

KUALA LUMPUR, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – A host of family-friendly activities is being rolled out by Subang Parade, a mall owned by Hektar Real Estate Investment Trust (Hektar REIT), taking inspiration from the theme for the country’s National Day, “Keluarga Malaysia Teguh Bersama”, or “Malaysian Family, Strong Together” while supporting... » read more

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 23... » read more

Avantor and Avantor Foundation Make a Difference by Providing Critical Health Services for Vulnerable Communities in Singapore
Avantor and Avantor Foundation Make a Difference by Providing Critical Health Services for Vulnerable Communities in Singapore

Singapore, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – Avantor Foundation, Avantor’s philanthropic arm, committed financial resources to healthcare charitable organizations, HealthServe and SATA CommHealth, as part of the Foundation’s mission to provide healthcare to those in need. The grants will offer much-needed support to communities who would otherwise be unable to receive quality... » read more

REDSUN SERVICES’s 2022 Interim Profit Attributable to Equity Shareholders Increases 15.8% to RMB69.3 million
REDSUN SERVICES’s 2022 Interim Profit Attributable to Equity Shareholders Increases 15.8% to RMB69.3 million

HONG KONG, Aug 23, 2022 – (ACN Newswire via SEAPRWire.com) – Redsun Services Group Limited (“Redsun Services” or the “Group”), a fast-growing comprehensive community services provider with a strong presence in the Yangtze River Delta region, has announced its interim results for the period ended 30 June 2022. The Group reported collaborative development in its... » read more

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease
Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

LAUSANNE, Switzerland, Aug 23, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on... » read more